Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inotuzumab ozogamicin in pediatric relapsed or refractory CD22-positive acute lymphoblastic leukemia
2023-504694-20-00Phase 2Authorised
- Sponsor
- Erasmus MC
- Start
- Oct 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 16
01
Overview
Phase 2, open-label trial of inotuzumab ozogamicin in acute lymphoblastic leukemia (ALL), B-cell malignancy, diffuse large B-cell lymphoma (DLBCL) and 4 more (7 arms), sponsored by Erasmus MC. Primary endpoints: Dose-limiting toxicities during first cycle, Overall response rate and 7 more. Planned start Oct 2023; status: authorised.
02
Drugs
inotuzumab ozogamicin
03
Conditions
acute lymphoblastic leukemia (ALL)B-cell malignancydiffuse large B-cell lymphoma (DLBCL)primary mediastinal large B-cell lymphoma (PMBCL)Burkitt lymphoma (BL)
Beyond the preview
Go deeper on 2023-504694-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504694-20-00.